Pregabalin (Lyrica ) Powder

Pregabalin, commonly known as Lyrica, is a medication that has gained popularity over the years for its effectiveness in treating a variety of medical conditions. It is a type of anti-epileptic drug that is primarily used to manage seizures, anxiety disorders, and neuropathic pain. Pregabalin works by regulating the activity of specific neurotransmitters in the brain that are responsible for transmitting pain signals. It is available in various forms, including capsules, tablets, and powders, to cater to different patient needs. In this article, we will explore the effectiveness and safety of pregabalin powder as a treatment for various medical conditions.

The medication called Pregabalin Powder is a type of amino acid that works as an anticonvulsant, analgesic, and anxiolytic drug. It is commonly used to treat a variety of conditions such as epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, opioid withdrawal, and generalized anxiety disorder. Additionally, Pregabalin has the added benefit of having antiallodynic properties.

Synonyms: 3(S)-(AMINOMETHYL)-5-METHYLHEXANOIC ACID;(3S)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID;PREGABALIN;Pregablin;3-(Aminomethyl)-5-methyl-hexanoic acid; PREDNISOLONESODIUMPHOSPHATE;(R)-Pregabalin;(S)-Pregabalin

CAS: 148553-50-8
MF: C8H17NO2
MW: 159.23
EINECS: 200-659-6
Product Categories: APIs;Miscellaneous Biochemicals;Intermediates & Fine Chemicals;Neurochemicals;Pharmaceuticals;API;compounds;LYRICA
Mol File: 148553-50-8.mol

Chemical Properties Of Pregabalin(Lyrica) Powder

MP  194-196°C
storage temp.  Store at RT
Appearance Off-White Solid

Safety Information:

Hazard Codes  Xn,T,F
Risk Statements  63-48/22-39/23/24/25-23/24/25-11
Safety Statements  22-36/37-45-16-7

Usage And Synthesis:
Usage
1.Pregabalin is an anticonvulsant drug used for neuropathic pain, as an adjunct therapy for partial seizures, and in generalized anxiety disorder. It was designed as a more potent successor to gabapentin.

2.S-Enantiomer of Pregabalin. A GABA analogue used as an anticonvulsant. Anxiolytic analgesic used to treat peripheral neuropathic pain and fibromyalgia..

Background

Pregabalin (Lyrica) Powder is a structural analogue of gamma-aminobutyric acid (GABA) but is novel in its activity, having no effects on GABA-A or GABA-B receptors.  Instead, the neuronal acitivity of pregabalin appears to be mediated by its binding to the alpha-2-delta subunit of the presynaptic voltage-gated calcium channel whcih leads to a decrease in release of neuroexcitatory neurotransmitters by hyperexcited neurons.  Pregabalin has been shown to be effective in reducing neuropathic pain from diabetic and postherpetic neuropathy and is an effective anticonvulsant.  Pregabalin was approved for use in the United States in 2004.  Current indications include diabetic and post-herpetic neuropathy and

as adjunctive therapy of partial onset seizures. Pregabalin is also used for fibromyalgia and off-label for generalized anxiety disorders and migraine.  Pregabalin is available in capsules in varying concentrations from 25 to 300 mg under the brand name of Lyrica.  The recommended initial dose for neuropathic pain is 50 to 75 mg two to three times daily, the maximum dose being 300 mg daily.  Higher doses are used in treating seizures.  The dose should be increased and tapered gradually.  The most common side effects of pregabalin are dose related and include peripheral edema, weight gain, dizziness, somnolence, confusion, headache, blurred vision, tremor and ataxia.

Hepatotoxicity

Limited data is available on the hepatotoxicity of pregabalin.  In prelicensure clinical trials in diabetic neuropathy and epilepsy, therapy with pregabalin was not associated with an increased frequency of serum aminotransferase elevations or liver toxicity.  Since its approval and more wide scale use, however, pregabalin has been linked to rare instances of clinically apparent liver injury.  Most cases were mild and frequently without jaundice.  The latency to onset of injury was short, symptoms of liver injury arising within 3 to 14 days.  Both cholestatic and hepatocellular patterns of injury have been reported.  Signs of hypersensitivity (fever, rash, eosinophilia) and autoimmunity were not present.  Some cases have been severe and associated with marked jaundice and prolongation of the prothrombin time, but all cases
ultimately resolved after the medication was stopped without evidence of residual injury.

Mechanism of Injury

The low rate of significant hepatotoxicity from pregabalin may be due to its minimal hepatic metabolism and rapid urinary excretion.  The injury is clearly idiosyncratic and either immunologic or metabolic causes are possible.

Outcome and Management

The case reports of hepatic injury due to pregabalin were followed by complete recovery without evidence of residual or chronic injury. There is no information about cross reactivity with other compounds having similar structure (gabapentin).